Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRX-102 · 4 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| PRX-102 (pegunigalsidase alfa) | BIOLOGICAL | PRX-102 1 mg/kg every 2 weeks |
| agalsidase beta | BIOLOGICAL | agalsidase beta 1 mg/kg every 2 weeks |
| PRX-102 | DRUG | - |
PRX-102 is an investigational drug being developed for the treatment of Fabry disease, a rare genetic disorder. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities. The drug is being studied to evaluate its safety and efficacy in patients with this condition.
PRX-102 is being developed by Protalix BioTherapeutics, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol PLX. Protalix is focused on developing therapies for rare diseases, and PRX-102 is one of its key investigational candidates for Fabry disease.
PRX-102 is currently in Phase 3 clinical development for Fabry disease. It has completed four clinical trials, including two Phase 3 studies. The drug is still investigational and has not received FDA approval. Its safety and efficacy are being evaluated in patients with Fabry disease.
PRX-102 has completed four clinical trials for Fabry disease. These include NCT01678898, a dose-ranging study; NCT01981720, an extension study; NCT02795676, a Phase 3 study comparing PRX-102 to agalsidase beta on renal function; and NCT03018730, a Phase 3 study in patients currently treated with REPLAGAL (agalsidase alfa).
No, PRX-102 is not the same as REPLAGAL (agalsidase alfa). PRX-102 is a separate investigational drug being developed by Protalix BioTherapeutics. One of its Phase 3 trials (NCT03018730) specifically studied PRX-102 in patients with Fabry disease who were already being treated with REPLAGAL.